We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Resection and reconstruction with and without neoadjuvant denosumab in campanacci grade III giant cell tumors of proximal humerus: a retrospective comparative study.
- Authors
Sahito, Badaruddin; Ali, Sheikh Muhammad Ebad; Farooqui, Sofia Fatima; Abro, Awais; Ahmed, Javed; Younis
- Abstract
Background: Giant cell tumors (GCT) of the proximal humerus are rarely reported case that requires complex surgeries due to involvement of the shoulder joint. Therefore, we report the first retrospective comparative study where the postoperative functional outcomes, recurrence rate and complications in patients who underwent arthrodesis of shoulder after resection of grade III GCT with and without neoadjuvant denosumab are compared. Methods: A retrospective review of eight cases of grade III GCT of proximal humerus receiving resection and fibular strut graft and arthrodesis between January 2014 and December 2019 is performed. They were stratified into two groups: one group of four patients received once-weekly denosumab 120 mg for 4-weeks before resection and reconstruction, while the other group of four patients did not receive denosumab before surgery. Primary outcomes included the functional outcomes assessed by revised Musculoskeletal tumor society (MSTS) score and shoulder pain and disability index (SPDI) at 6-weeks and 12-months postoperatively while secondary outcomes included complications and recurrences. Results: There was no significant difference in terms of SPDI at 6 weeks and 12 months, MSTS at 12 months, complications, recurrence among denosumab and non-denosumab groups. At 6-weeks follow-up, a significantly better pain score in SPDI and MSTS was acquired in the denosumab group. Conclusions: Resection and reconstruction with or without neoadjuvant denosumab for Grade III GCT of proximal humerus had similar functional outcomes and with no major differences in recurrence and complications. Hence, postoperative pain relief while long-term benefits were not discovered with the use of neoadjuvant denosumab.
- Subjects
THERAPEUTIC use of monoclonal antibodies; ARTHRODESIS; FUNCTIONAL status; GIANT cell tumors; PLASTIC surgery; SURGICAL complications; RETROSPECTIVE studies; BONE tumors; TREATMENT effectiveness; DISEASE relapse; COMPARATIVE studies; HUMERUS; DESCRIPTIVE statistics; COMBINED modality therapy
- Publication
European Journal of Orthopaedic Surgery & Traumatology, 2023, Vol 33, Issue 1, p81
- ISSN
1633-8065
- Publication type
Article
- DOI
10.1007/s00590-021-03162-2